|
1
|
Kang I and Bucala R: The immunobiology of
MIF: Function, genetics and prospects for precision medicine. Nat
Rev Rheumatol. 15:427–437. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bloom J, Sun S and Al-Abed Y: MIF, a
controversial cytokine: A review of structural features,
challenges, and opportunities for drug development. Expert Opin
Ther Targets. 20:1463–1475. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu A, Bao F and Voravuthikunchai SP: CATT
polymorphism in MIF gene promoter is closely related to human
pulmonary tuberculosis in a southwestern China population. Int J
Immunopathol Pharmacol. May 29–2018.(Epub ahead of print). doi:
10.1177/2058738418777108.
|
|
4
|
Matia-García I, Salgado-Goytia L,
Muñoz-Valle JF, García-Arellano S, Hernández-Bello J,
Salgado-Bernabé AB and Parra-Rojas I: Macrophage migration
inhibitory factor promoter polymorphisms (−794 CATT 5–8 and −173
G>C): Relationship with mRNA expression and soluble MIF levels
in young obese subjects. Dis Markers. 2015:4612082015. View Article : Google Scholar
|
|
5
|
Yao J, Leng L, Sauler M, Fu W, Zheng J,
Zhang Y, Du X, Yu X, Lee P and Bucala R: Transcription factor
ICBP90 regulates the MIF promoter and immune susceptibility locus.
J Clin Invest. 126:732–744. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mousli M, Hopfner R, Abbady AQ, Monté D,
Jeanblanc M, Oudet P, Louis B and Bronner C: ICBP90 belongs to a
new family of proteins with an expression that is deregulated in
cancer cells. Br J Cancer. 89:120–127. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abbady AQ, Bronner C, Trotzier MA, Hopfner
R, Bathami K, Muller CD, Jeanblanc M and Mousli M: UHRF1 expression
is downregulated in apoptosis-induced Jurkat cells. Ann N Y Acad
Sci. 1010:300–303. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ashraf W, Ibrahim A, Alhosin M, Zaayter L,
Ouararhni K, Papin C, Ahmad T, Hamiche A, Mély Y, Bronner C and
Mousli M: The epigenetic integrator UHRF1: On the road to become a
universal biomarker for cancer. Oncotarget. 8:51946–51962. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen YC, Zhang XW, Niu XH, Xin DQ, Zhao
WP, Na YQ and Mao ZB: Macrophage migration inhibitory factor is a
direct target of HBP1-mediated transcriptional repression that is
overexpressed in prostate cancer. Oncogene. 29:3067–3078. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bollaert E, Johanns M, Herinckx G, de
Rocca Serra A, Vandewalle VA, Havelange V, Rider MH, Vertommen D
and Demoulin JB: HBP1 phosphorylation by AKT regulates its
transcriptional activity and glioblastoma cell proliferation. Cell
Signal. 44:158–170. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bollaert E, de Rocca Serra A and Demoulin
JB: The HMG box transcription factor HBP1: A cell cycle inhibitor
at the crossroads of cancer signaling pathways. Cell Mol Life Sci.
76:1529–1539. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li H, Wang W, Liu X, Paulson KE, Yee AS
and Zhang X: Transcriptional factor HBP1 targets P16(INK4A),
upregulating its expression and consequently is involved in
Ras-induced premature senescence. Oncogene. 29:5083–5094. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukaya R, Ohta S, Yaguchi T, Matsuzaki Y,
Sugihara E, Okano H, Saya H, Kawakami Y, Kawase T, Yoshida K and
Toda M: MIF maintains the tumorigenic capacity of brain
tumor-initiating cells by directly inhibiting p53. Cancer Res.
76:2813–2823. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharaf-Eldein M, Elghannam D, Elderiny W
and Abdel-Malak C: Prognostic implication of MIF gene expression in
childhood acute lymphoblastic leukemia. Clin Lab. 64:1429–1437.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumar S, O'Malley J, Chaudhary AK, Inigo
JR, Yadav N, Kumar R and Chandra D: Hsp60 and IL-8 axis promotes
apoptosis resistance in cancer. Br J Cancer. 121:934–943. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuett A, Rieger C, Perathoner D, Herold T,
Wagner M, Sironi S, Sotlar K, Horny HP, Deniffel C, Drolle H and
Fiegl M: IL-8 as mediator in the microenvironment-leukaemia network
in acute myeloid leukaemia. Sci Rep. 5:184112015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vijay V, Miller R, Vue GS, Pezeshkian MB,
Maywood M, Ast AM, Drusbosky LM, Pompeu Y, Salgado AD, Lipten SD,
et al: Interleukin-8 blockade prevents activated endothelial cell
mediated proliferation and chemoresistance of acute myeloid
leukemia. Leuk Res. 84:1061802019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bilsborrow JB, Doherty E, Tilstam PV and
Bucala R: Macrophage migration inhibitory factor (MIF) as a
therapeutic target for rheumatoid arthritis and systemic lupus
erythematosus. Expert Opin Ther Targets. 23:733–744. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Noe JT and Mitchell RA: MIF-dependent
control of tumor immunity. Front Immunol. 11:6099482020. View Article : Google Scholar : PubMed/NCBI
|
